Anebulo Pharmaceuticals Inc

NASDAQ ANEB

Data sourced from iex and EODHD
Download Data

Anebulo Pharmaceuticals Inc Accounts Payable 1 year YoY Change (%) for the quarter ending March 31, 2024: -32.58%

Anebulo Pharmaceuticals Inc Accounts Payable 1 year YoY Change (%) is -32.58% for the quarter ending March 31, 2024, a -105.56% change year over year. Accounts Payable are amounts owed by the company to suppliers or vendors for goods or services received but not yet paid. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Anebulo Pharmaceuticals Inc Accounts Payable for the quarter ending March 31, 2023 was USD 570.90 K, a 585.55% change year over year.
  • Anebulo Pharmaceuticals Inc Accounts Payable for the quarter ending March 31, 2022 was USD 83.28 K, a 1.52% change year over year.
  • Anebulo Pharmaceuticals Inc Accounts Payable for the quarter ending March 31, 2021 was USD 82.03 K.
NASDAQ: ANEB

Anebulo Pharmaceuticals Inc

CEO Dr. Joseph F. Lawler M.D., Ph.D.
IPO Date May 7, 2021
Location United States
Headquarters 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734
Employees 2
Sector Healthcare
Industry Biotechnology
Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email